Over time, Adeno-associated virus (AAV) vectors have become the leading platform for gene delivery in the potential treatment of a variety of human diseases.
Researchers and bioanalytical scientists within the gene therapy community have focused on characterizing various AAV serotypes using conventional and next-generation technologies to deliver critical quality attributes along their workflow.
In this application note, discover how AlphaLISA® and LabChip® GXII Touch™ microfluidics-based CE technology can be used as orthogonal methodologies to detect and characterize AAV8 serotype capsid proteins.